APA

Nijhuis M., Wensing A. M. J., Bierman W. F. W., de Jong D., Kagan R., Fun A., Jaspers C. A. J. J., Schurink K. A. M., van Agtmael M. A. & Boucher C. A. B. (20090924). Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V. : The Journal of infectious diseases.

Chicago

Nijhuis Monique, Wensing Annemarie M J, Bierman Wouter F W, de Jong Dorien, Kagan Ron, Fun Axel, Jaspers Christian A J J, Schurink Karin A M, van Agtmael Michael A and Boucher Charles A B. 20090924. Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V. : The Journal of infectious diseases.

Harvard

Nijhuis M., Wensing A. M. J., Bierman W. F. W., de Jong D., Kagan R., Fun A., Jaspers C. A. J. J., Schurink K. A. M., van Agtmael M. A. and Boucher C. A. B. (20090924). Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V. : The Journal of infectious diseases.

MLA

Nijhuis Monique, Wensing Annemarie M J, Bierman Wouter F W, de Jong Dorien, Kagan Ron, Fun Axel, Jaspers Christian A J J, Schurink Karin A M, van Agtmael Michael A and Boucher Charles A B. Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V. : The Journal of infectious diseases. 20090924.